92
Participants
Start Date
August 31, 2013
Primary Completion Date
November 30, 2024
Study Completion Date
May 31, 2025
TPI 287
TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
Bevacizumab
Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
The Long Island Brain Tumor Center at Neurological Surgery, P.C., Lake Success
The Long Island Brain Tumor Center at Neurological Surgery, P.C., Commack
University of Rochester Medical Center, Rochester
University of Alabama at Birmingham, Birmingham
The Ohio State University Wexner Medical Center, Columbus
Washington University School of Medicine, St Louis
Memorial Hermann Hospital, Houston
Swedish Neuroscience Institute, Seattle
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
Lead Sponsor
Cortice Biosciences, Inc.
INDUSTRY